| 產(chǎn)品名稱 |
S4B6-1 |
| 商品貨號 |
B165655 |
| Organism |
Rattus norvegicus (B cell); Mus musculus (myeloma), rat (B cell); mouse (myeloma) |
| Cell Type |
hybridoma: B lymphocyte |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain |
Strain:? Lewis (B cell); BALB/c (myeloma) |
| Applications |
This is a supplemental deposit of the S4B6 hybridoma (ATCC HB-8794) that has improved antibody production. The cells secrete immunoglobulin (rat IgG2a) for a short period in culture. The antibody binds to mouse IL-2 and neutralizes mouse IL-2 activity. |
| Storage Conditions |
liquid nitrogen vapor phase |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with Sp2/0 myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against mouse interleukin 2 (interleukin-2, IL-2) |
| Cellular Products |
immunoglobulin; monoclonal antibody; against mouse interleukin 2 (interleukin-2, IL-2) |
| Tumorigenic |
Yes |
| Effects |
Yes, forms ascites in pristane primed and immunosuppressed BALB/c mice (irradiated 150R to 450 R) |
| Comments |
This is a supplemental deposit of the S4B6 hybridoma (ATCC HB-8794) that has improved antibody production. Animals were immunized with supernatant from a mouse helper T cell line (LB2-1, see ATCC CRL-8629). Spleen cells were fused with Sp2/0 myeloma cells. The cells secrete immunoglobulin (rat IgG2a) for a short period in culture. To grow as ascites, inject 2 X 10 exp6 cells/ml into BALB/c mice primed one week earlier with 0.5 ml pristane and given 150R to 450R of gamma irradiation. The antibody binds to mouse IL-2 and neutralizes mouse IL-2 activity. It does not react with rat or human IL-2. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Protocol: Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10(5) cells/ml and maintain between 1 X 10(5) and 2 X 10(6) cells/ml. Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density) |
| Cryopreservation |
Freeze medium: culture medium 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
| Culture Conditions |
Atmosphere: air, 95%; carbon dioxide (CO2), 5% Temperature: 37.0°C |
| Isotype |
IgG2a |
| Name of Depositor |
DNAX Research Institute of Molecular and Cellular Biology, Inc. |
| Deposited As |
rat (B cell); mouse (myeloma) |
| U.S. Patent Number |
|
| References |
Mosmann TR. Hybridoma cell lines producing monoclonal antibodies which specifically bind to mouse interleukin-2. US Patent 4,690,893 dated Sep 1 1987
|
